Background Sickle cell disease (SCD) is a genetic disease that impacts patients' quality of
life, healthcare costs, and life expectancy. Elevated sickle hemoglobin (HbS), which readily …

Objectives The aim of this single‐center chart review was to quantify the hematologic
response and validated reported outcomes with voxelotor treatment. Methods Real‐world …

New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …

Voxelotor, a sickle hemoglobin polymerization inhibitor, was approved by the US Food and
Drug Administration to treat sickle cell disease (SCD) in November 2019. This article …

Voxelotor (Oxbryta™) is a haemoglobin S polymerization inhibitor that has been developed
for the treatment of sickle cell disease. In November 2019, voxelotor received its first global …

Background Sickle cell disease (SCD) is a devastating, multisystemic disorder that affects
millions of people worldwide. The earliest clinical manifestations of SCD can affect infants as …

Abstract Background Deoxygenated sickle hemoglobin (HbS) polymerization drives the
pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has …

Objective: To review the pharmacological characteristics, clinical evidence, and place in
therapy of voxelotor for the treatment of sickle cell disease (SCD). Data Sources: A …

Background For decades, patients with sickle cell disease have had only a limited number of
therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin …

Introduction: The clinical manifestations of sickle cell disease (SCD) result from an inherited
mutation in the beta-globin chain of hemoglobin (Hb) that causes Hb tetramers to polymerize …